PTC Therapeutics, Inc. (PTCT) Q2 2026 Earnings Call Transcript

SA Transcripts 161.36K Followers Follow PTC Therapeutics, Inc. ( PTCT ) Q2 2026 Earnings Call July 30, 2026 4:30 PM EDT Company Participants Ellen Cavaleri - Head of Investor Relations Matthew Klein - CEO & Director Eric Pauwels - Chief Business Officer Pierre Gravier - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Tazeen Ahmad - BofA Securities, Research Division Eliana Merle - Barclays Bank PLC, Research Division Eric Joseph - Citigroup Inc., Research Division Benjamin Burnett - Wells Fargo Securities, LLC, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Judah Frommer - Morgan Stanley, Research Division Joseph Thome - TD Cowen, Research Division Faisal Khurshid - Jefferies LLC, Research Division Nevin Varghese - RBC Capital Markets, Research Division Luke Herrmann - Robert W. Baird & Co. Incorporated, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. Welcome to PTC Therapeutics Second Quarter 2026 Earnings Conference Call. [Operator Instructions] Today's conference is being recorded. I would now like to turn the conference over to Ellen Cavaleri, Head of Investor Relations. Please go ahead. Ellen Cavaleri Head of Investor Relations Good afternoon, and thank you for joining us to discuss PTC Therapeutics' Second Quarter 2026 Corporate Update and Financial Results. I'm joined today by our Chief Executive Officer, Dr. Matthew Klein; our Chief Business Officer, Eric Pauwels; and our Chief Financial Officer, Pierre Gravier. Today's call will include forward-looking statements based on our current expectations. These statements are subject to certain risks and uncertainties, and actual results may differ materially. Please review the slide posted on our Investor Relations website in conjunction with the call, which contains information about our forward-looking statements and our most recent quarterly report on Form 10-Q and annual report on Form 10-K filed with the SEC as well as